UK
Health analytics
Global market access strategy
Our strategic services help clients to navigate uncertainties and maximize value throughout the product lifecycle.
We enable market access through provision of insights that inform development of optimal payer evidence, pricing and access strategies, while also providing solutions that help execute on the strategy and set our clients' assets up for commercial success. Our tailored approach aims to provide market access insights and solutions across all stages of the product lifecycle.
Connecting global value and access strategies to local health system needs and priorities
At LCP Health Analytics, we recognize that securing access and reimbursement for novel therapies requires a strategic approach tailored to each product and market. Our dedicated market access team goes beyond traditional consulting models to deliver an integrated, customized service aligned with your specific needs for value demonstration, pricing strategy, and payer engagement.
We foster early payer involvement through our global payer network for value demonstration, access, and pricing — enabling successful launches. Using real-world evidence, we quantify the full range of tangible and intangible value elements your product delivers to payers and health systems. We also bring deep experience in co-developing innovative, outcomes-based agreements that respond to evolving healthcare priorities.
With real-world analytics at the core of our market access approach, we stand apart from typical market access consultancies by connecting global value strategies with local health system priorities. Our goal is to help you achieve broad, rapid, and sustainable patient access.
We support our clients across the following areas:
Global market access consulting
- Pricing, reimbursement, and competitor landscape assessment
- Payer research/advisory boards
- Market access strategy/roadmap
- Portfolio planning including indication sequencing and country prioritization
- Business development/licensing evaluation i.e. opportunity assessment/asset due diligence
Payer value communications
- Value story/messaging
- Global value dossier strategy and development, including the Academy of Managed Care Pharmacy (AMCP) and formulary communications
- Payer value decks and access toolkits
- Objection handling
- Payer simulation workshops
- Internal training and preparedness
- Payer-focused publications
Payer evidence generation strategy
- Evidence gap analysis
- Data source landscaping
- Assessment of payer acceptability
- Payer rationalized clinical trial design
- Development of cross-functional, real-world evidence strategy across the lifecycle
Our global market access strategy team work closely with our US access solutions team who cover US focused pricing and reimbursement, patient services and trade and channel services.
Medicines Nexus™
Prescription analytics platform
Our innovative prescription analytics platform delivering cutting-edge insights into the medicines market.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
